Nash-Related Cirrhosis
The Intersection of NASH and Cardiometabolic Diseases: Implications For Screening, Diagnosis, and Management
This activity is supported by an educational grant from Novo Nordisk.
Obeticholic acid flops in phase 3 trial for compensated NASH-related cirrhosis
Obeticholic acid failed to demonstrate superiority to placebo for improving fibrosis in patients with compensated cirrhosis due to nonalcoholic steatohepatitis in a phase 3 trial, according to an Intercept Pharmaceuticals press release.
Rare germline mutations in CIDEB gene protect against liver disease, damage
In one of the largest exome-sequencing studies on liver health, researchers found rare genetic loss-of-function variants in the CIDEB gene were associated with significant protection from liver damage and disease.
Top in GI: Ozempic in NASH-related cirrhosis; infection risk with PPIs
During the International Liver Congress, researchers presented 48-week trial data that showed once-weekly Ozempic improved cardiometabolic markers but not liver fibrosis in patients with nonalcoholic steatohepatitis and compensated cirrhosis.